Cargando…

Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy

Cardiovascular diseases (CVDs) are currently among the leading causes of death worldwide. Platelet aggregation is a key cellular component of arterial thrombi and major cause of CVDs. Protease-activated receptors (PARs), including PAR1, PAR2, PAR3 and PAR4, fall within a subfamily of seven-transmemb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rwibasira Rudinga, Gamariel, Khan, Ghulam Jilany, Kong, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855795/ https://www.ncbi.nlm.nih.gov/pubmed/29443899 http://dx.doi.org/10.3390/ijms19020573

Ejemplares similares

Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics
por: Tourdot, Benjamin E., et al.
Publicado: (2018)

A Naphthalenic Derivative ND-1 Inhibits Thrombus Formation by Interfering the Binding of Fibrinogen to Integrin αIIbβ3
por: Ding, Xue, et al.
Publicado: (2016)

Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer
por: Liu, Xuan, et al.
Publicado: (2017)

Complement factor C4a does not activate protease‐activated receptor 1 (PAR1) or PAR4 on human platelets
por: Han, Xu, et al.
Publicado: (2020)

Calcium Mobilization And Protein Kinase C Activation Downstream Of Protease Activated Receptor 4 (PAR4) Is Negatively Regulated By PAR3 In Mouse Platelets
por: Arachiche, Amal, et al.
Publicado: (2013)

Correction: Calcium Mobilization And Protein Kinase C Activation Downstream Of Protease Activated Receptor 4 (PAR4) Is Negatively Regulated By PAR3 In Mouse Platelets
por: Arachiche, Amal, et al.
Publicado: (2013)

A biological target for antiplatelet therapy: the prostaglandin E(2) receptor EP(4)
por: Philipose, Sonia, et al.
Publicado: (2010)

Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition
por: Meah, Mohammed N., et al.
Publicado: (2020)

PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation
por: Wilson, Simon J., et al.
Publicado: (2018)

Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis
por: Lin, Cong, et al.
Publicado: (2015)

Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy
por: Ocasio-Rivera, Marinel, et al.
Publicado: (2020)

Protease Activated Receptor 2 (PAR2) Induces Long-Term Depression in the Hippocampus through Transient Receptor Potential Vanilloid 4 (TRPV4)
por: Shavit-Stein, Efrat, et al.
Publicado: (2017)

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring
por: Krammer, Teresa L., et al.
Publicado: (2020)

Novel Role for Proteinase-activated Receptor 2 (PAR(2)) in Membrane Trafficking of Proteinase-activated Receptor 4 (PAR(4))
por: Cunningham, Margaret R., et al.
Publicado: (2012)

Histone 2B Facilitates Plasminogen-Enhanced Endothelial Migration through Protease-Activated Receptor 1 (PAR1) and Protease-Activated Receptor 2 (PAR2)
por: Das, Mitali, et al.
Publicado: (2022)

Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases
por: Heuberger, Dorothea M., et al.
Publicado: (2019)

Molecular cloning of the rat proteinase-activated receptor 4 (PAR4)
por: Hoogerwerf, Willemijntje A, et al.
Publicado: (2002)

Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2015)

Protease‐activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model
por: Berry, Jess, et al.
Publicado: (2022)

Correction to: protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases
por: Heuberger, Dorothea M., et al.
Publicado: (2019)

Thrombin Receptor Antagonism in Antiplatelet Therapy
por: Olivier, C., et al.
Publicado: (2013)

Emerging Roles of Protease-Activated Receptors (PARs) in the Modulation of Synaptic Transmission and Plasticity
por: Price, Rachel, et al.
Publicado: (2021)

Humanizing the Protease-Activated Receptor (PAR) Expression Profile in Mouse Platelets by Knocking PAR1 into the Par3 Locus Reveals PAR1 Expression Is Not Tolerated in Mouse Platelets
por: French, Shauna L., et al.
Publicado: (2016)

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls
por: Ellithi, Moataz, et al.
Publicado: (2020)

Predictive value of protease‐activated receptor‐2 (PAR(2)) in cervical cancer metastasis
por: He, Shengnan, et al.
Publicado: (2020)

Role of protease‐activated receptor‐1 (PAR‐1) in the glomerular filtration barrier integrity
por: Medipally, Ajay, et al.
Publicado: (2022)

Chemical Tools to Image the Activity of PAR-Cleaving Proteases
por: Lee, Irene Y., et al.
Publicado: (2023)

Protease activated receptor 1 (PAR1) enhances Src-mediated tyrosine phosphorylation of NMDA receptor in intracerebral hemorrhage (ICH)
por: Duan, Zhen-Zhen, et al.
Publicado: (2016)

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013)

ClpP Protease, a Promising Antimicrobial Target
por: Moreno-Cinos, Carlos, et al.
Publicado: (2019)

Design of a novel integrated microfluidic chip for continuous separation of circulating tumor cells from peripheral blood cells
por: Bakhshi, Maliha Saleem, et al.
Publicado: (2022)

Bacterial serine protease HtrA as a promising new target for antimicrobial therapy?
por: Wessler, Silja, et al.
Publicado: (2017)

Transcription factor network downstream of protease activated receptors (PARs) modulating mouse bladder inflammation
por: Saban, Ricardo, et al.
Publicado: (2007)

Developmental Role of Zebrafish Protease-Activated Receptor 1 (PAR1) in the Cardio-Vascular System
por: Ellertsdottir, Elin, et al.
Publicado: (2012)

Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease
por: Wu, Linyu, et al.
Publicado: (2022)

Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease
por: Mamun, Abdullah Al, et al.
Publicado: (2020)

Attenuated Vasodilator Effectiveness of Protease-Activated Receptor 2 Agonist in Heterozygous par2 Knockout Mice
por: Hennessey, John C., et al.
Publicado: (2013)

Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma
por: Tas, Faruk, et al.
Publicado: (2016)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells
por: Cernaj, Ingeborg Elisabeth
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ktdpajs5q8aijujrb1ctl5fgs1